<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00545831</url>
  </required_header>
  <id_info>
    <org_study_id>2006/100/HP</org_study_id>
    <secondary_id>2007-A00618-45</secondary_id>
    <nct_id>NCT00545831</nct_id>
  </id_info>
  <brief_title>Effect of Taurolidin on Prevention of Bloodstream Infection</brief_title>
  <acronym>Nutrilock</acronym>
  <official_title>Prevention of Central Veinous Device Related Sepsis Relapse With Taurolidine in Patients on Parenteral Nutrition in Long-term Home</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Rouen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Rouen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Home parenteral nutrition (HPN) is a validated technique for patients with various intestinal
      disease leading to chronic malabsorption or obstruction, whatever the aetiology.
      Intravascular catheter-related bloodstream infections (CRBSI) is the more frequent
      complication of patients with HPN and an important cause of morbidity and mortality in these
      patients. Moreover, CRBSI often recur after a first treatment of the catheter with a
      combination of an antibiotic lock on the catheter and systemic intravenous antibiotics. In
      more than 50 % of the cases, another CRBSI will occur in a median delay of 5 months.

      The aim of the study is to evaluate the efficacy of a taurolidine lock secondary prophylaxis
      on CRBSI recurrence in HPN patients.

      Study population is separated in 2 groups, the first one receiving the Taurolock and the
      second one receiving a placebo. This is a randomized double-blind six-month study.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    lack of recruitment
  </why_stopped>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of recurrence of catheter-related infection in each group</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Sepsis</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Use of taurolidine in prevention of bloodstream infection related to central venous access</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Use of Physiologic Serum to compare to arm A</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Taurolidine</intervention_name>
    <description>2 mL of taurolidine instillate on the intravascular catheter after each parenteral nutrition session for a duration of 6 months</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Physiologic Serum</intervention_name>
    <description>2 mL of physiologic serum instillate on the intravascular catheter after each parenteral nutrition session for a duration of 6 months</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age superior to 18 years

          -  Home parenteral nutrition on tunnelized central venous catheters

          -  Bloodstream infection confirmed by differential hemocultures

          -  Informed consent form signed

          -  Negative B-HCG test

        Exclusion Criteria:

          -  Subject unable to give his informed consent

          -  Pregnancy

          -  Subject who have a two or three-way catheter, or a non-tunnelized central venous
             catheter

          -  Hospital related infection

          -  Central venous catheters placed since less than 15 days

          -  Neutropenia &lt; 500 PNN/mm3

          -  Fungal Infection, polymicrobial who need ablation of the central venous catheters

          -  No-response to clinical treatment of the Infection

          -  Septic thrombophlebitis

          -  Chemotherapy ongoing

          -  On going malignancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>St√©phane Lecleire, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Rouen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>APHP Beaujon Hospital</name>
      <address>
        <city>Clichy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UH of Grenoble</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UH of Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UH of Lyon</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UH of Nice</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Rouen</name>
      <address>
        <city>Rouen</city>
        <zip>76000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UH of Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 16, 2007</study_first_submitted>
  <study_first_submitted_qc>October 16, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2007</study_first_posted>
  <last_update_submitted>March 4, 2013</last_update_submitted>
  <last_update_submitted_qc>March 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 5, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Home Parenteral Nutrition</keyword>
  <keyword>Sepsis Prevention</keyword>
  <keyword>Central Venous Catheters</keyword>
  <keyword>Taurolidine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Taurolidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

